SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Guggenheim initiates Faeth Therapeutics at Buy; $70 price target

Benzinga reports Guggenheim initiated Faeth Therapeutics (FTH) with a Buy rating and a $70.00/share price target.

FTH

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.

Related stories